| HOME >> BIOLOGY >> TECHNOLOGY |
of earnings
per share:
Basic 1,075 1,075 1,127 1,127
Diluted (r) 1,079 1,078 (a) 1,133 1,131 (a)
(a) - (r) See explanatory notes on the following pages.
Amgen Inc.
Notes to Reconciliation of GAAP Earnings to "Adjusted" Earnings
(In millions, except per share data)
(Unaudited)
(a) To exclude the impact of stock option expense recorded in accordance
with Statement of Financial Accounting Standards ("SFAS") No. 123R.
For the three and nine months ended September 30, 2008 and 2007, the
total pre-tax expense for employee stock options in accordance with
SFAS No. 123R was $25 million and $42 million, respectively, and $77
million and $140 million, respectively.
"Adjusted" diluted EPS including the impact of stock option expense
for the three and nine months ended September 30, 2008 and 2007 was
as follows:
Three months ended Nine months ended
September 30, September 30,
------------------ -----------------
2008 2007 2008 2007
------------------ -----------------
"Adjusted" diluted EPS,
excluding stock option
expense $1.23 $1.08 $3.49 $3.29
Impact of stock option
expense (net of tax) (0.02) (0.02) (0.05) (0.09)
------- ------- ------- -------
"Adjusted" diluted EPS,
including stock option
expense $1.21 $1.06 $3.44 $3.20
======= ======= ======= =======
(
'/>"/>
| SOURCE Amgen Copyright©2008 PR Newswire. All rights reserved |